Skip to content
According to the European Innovative ScoreBoard (EIS), the level of innovation in a country is particularly relevant for life sciences companies when choosing a […]
Western Switzerland: Collaboration is the key to a robust life sciences sector Read More »
The challenge of preventing pharmacy benefit managers (PBMs) from driving up drug prices was front and center on Capitol Hill this week. Bipartisan legislation
Congress puts PBMs in the spotlight during a busy week on Capitol Hill Read More »
Sutro Biopharma, Inc., a clinical-stage drug discovery, development, and manufacturing company, has made significant advancements in the field of antibody-drug conjugates (ADCs). Their innovative
Sutro Biopharma in clinical stages for groundbreaking cancer treatment Read More »
With the deadly threat of drug-resistant infections increasing daily, we desperately need actions to address the broken commercial marketplace for novel antimicrobials—including the PASTEUR
Legislation to fight AMR superbugs is an urgent need, BIO member tells Senate hearing Read More »
The Senate Health, Education, Labor, and Pensions (HELP) Committee released a bipartisan discussion draft of the Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization bill
Senate HELP’s PAHPA draft: The good, the bad, and the ugly Read More »
Panelists came together in a session titled “Gene Therapy: Let’s Talk about Safety, Baby,” at the 2023 Biotechnology Innovation Organization (BIO) International Convention. Gene
Gene therapy: Let’s talk about safety Read More »
The U.S. Food and Drug Administration (FDA) granted traditional approval to the groundbreaking Alzheimer’s drug LEQEMBI, the first in a new class of Alzheimer’s
FDA grants traditional approval to LEQEMBI Read More »
With so many life-science advances starting on the farm, the 2023 Farm Bill, which sets U.S. agriculture policy for the next five years, is
Why the 2023 Farm Bill matters to biotech Read More »
According to the World Health Organization (WHO), “Cardiovascular disease (CVD) is a leading public health (and economic issue) in the United States,” a fact
Navigating patient access barriers to solve public health challenges in CVD Read More »
After the Centers for Medicare & Medicaid Services (CMS) released its guidance for the Drug Price Negotiation Program (Negotiation Program) under the Inflation Reduction
BIO: New CMS guidance a ‘missed opportunity’ for future medical innovation, patients Read More »
